Navigation Links
Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007
Date:11/6/2007

sion of enzymes-proteins that act as the catalysts of biochemical reactions.

Verenium operates one of the nation's first cellulosic ethanol pilot plants, an R&D facility, in Jennings, Louisiana and expects to achieve mechanical completion of a 1.4 million gallon-per-year, demonstration-scale facility to produce cellulosic ethanol by the end of the first quarter of 2008. In addition, the Company's process technology has been licensed by Tokyo-based Marubeni Corp. and Tsukishima Kikai Co., Ltd. and has been incorporated into BioEthanol Japan's 1.4 million liter-per-year cellulosic ethanol plant in Osaka, Japan -- the world's first commercial-scale plant to produce cellulosic ethanol from wood construction waste. For more information on Verenium, visit http://www.verenium.com.

Forward Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include statements related to the Company's market opportunities and the Company's abilities to take advantage of those opportunities, technological progress in both its Biofuels and Specialty Enzymes Business Unit and the expected benefits from that progress, future gross profits and product gross margins, fair value estimates for the allocation of the Celunol merger consideration, timing for mechanical completion of the Jennings demonstration plant, timing for completing, and expected benefits to be derived from, the start-up phase of the Jennings demonstration plant, reorganization of its Specialty Enzymes Business Unit sales and marketing team and its product portfolio review in its Specialty Enzymes Business Unit, and the expected benefits from both activities, and corporate strategy, including as it relates to strategic partnering activities, funding activities, and public policy activities all of which are prospective. Such statements are only predicti
'/>"/>

SOURCE Verenium Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2008)...a quick fix without losing taste, experts say , ...u can eat healthier this holiday season by alterin...s with the Texas AgriLife Extension Service. ,...ontent of almost any holiday recipe without a noti...ary Bielamowicz said in a news release. , "If ...
(Date:11/21/2008)...man, fresh from basic training and now serving ove...se life he saved by donating his rare blood type. ...ic of Korea (PRWEB) November 21, 2008 -- A local K...onation saved her life, met for the first time whe..., , ,Airman Tamarias Pope, 8th Security Forces Squ...
(Date:11/21/2008)...for preterm labor , , FRIDAY, Nov. 21 (H...e switch that activates the uterine muscles for co...ad to therapies for preterm labor. , The molec...the surface of these uterine muscle cells, keeping...But researchers from Dartmouth Medical School in N...
(Date:11/21/2008)... be held on January 8, 2009 , , TORONTO, No...onal Inc. ("MedEmerg") (OTCBB: MDER), one of Canad...d today that it has obtained an interim order from...its previously announced plan of arrangement (the ...Inc. ("AIM") will acquire all of MedEmerg,s outsta...
Breaking Medicine News(10 mins):Health News:Substitutions Make Holiday Fare Healthier 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3
...) is one of the most common behavioral disorders i...be to blame for some ODD cases. Researchers in, O...e diagnosed with a migraine condition. //Participa...rther evaluated during a psychological interview. ...
Stem cells are the basic building blocks of animals, forming in the new embryo and later developing into the various organs and tissues as the fetus grows. The work is very preliminary, and was done
...anned Parenthood clinic two weeks ago to quietly c...ady for. One week later, the 18-year-old lay dying...ications after she took the abortion pill. Patters...ate surrounding RU-486, the pill approved by the F...
...n relief for women during childbirth. A study don...uce the sensation of labour pain and delay the emo...he study included two groups of women, aged 20 to ...Women in one group chose from among five types of ...
Other Medicine News:Health News:Teen dies after complications from abortion pill 2
(Date:11/21/2008)...nd, November 21 , ...mmittee for Medicinal Products for Human Use (CHMP... the approval of Enbrel(R),(etanercept) as a trea...escents with severe plaque psoriasis. If approved ...ee,s recommendation, Enbrel will become the,first...
(Date:11/20/2008)... , PHILADELPHIA, Nov. 20 /PRNewswire-FirstCall... that the United States Food and Drug Administrati...(R) (eltrombopag) for the treatment of thrombocyto... thrombocytopenic purpura (ITP) who have had an in...ulins or splenectomy. The approval is a significan...
(Date:11/20/2008)... Nov. 20 Duska Therapeut...today that it has submitted its,pivotal Phase 3 A...pecial,Protocol Assessment (SPA) procedure with t... Subject to securing an agreement with the FDA,... double-blind, placebo-controlled and randomized P...
(Date:11/19/2008)...v. 19 Posit Science Corporation,r...ociety for Neuroscience,Annual Conference in Wash...aining may benefit Baby Boomers. The computerized...) uses adaptive exercises that target auditory and... drive generalized,improvements in cognition by i...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Immigrants From India Pakistan Face U S Prostate Breast Cancer Risks 2974 1Immigrants From India Pakistan Face U S Prostate Breast Cancer Risks 2974 2Extra payments to Medicare Advantage plans to total 248 5 billion in 2008 26084 1Extra payments to Medicare Advantage plans to total 248 5 billion in 2008 26084 2ISU researchers help map first plant parasitic nematode genome sequence 4736 1ISU researchers help map first plant parasitic nematode genome sequence 4736 2Zimmer Holdings Inc Announces Agreement to Acquire Abbott Spine an Innovator in Spinal Technology 7493 1Zimmer Holdings Inc Announces Agreement to Acquire Abbott Spine an Innovator in Spinal Technology 7493 2Zimmer Holdings Inc Announces Agreement to Acquire Abbott Spine an Innovator in Spinal Technology 7493 3Zimmer Holdings Inc Announces Agreement to Acquire Abbott Spine an Innovator in Spinal Technology 7493 4
...March 8, 2007--The World Health Organization,has r... rising in,Pakistan. , So is this another instance...armaceutical industry is denying important vaccine...rding to London’s Guardian,newspaper, &ldquo...efused to allow health workers to administer polio...
...USINESS WIRE)--Mar 8, 2007 - Magen BioSciences,In...ed the,publication of a paper in the March 9, 2007...oard member, David E. Fisher, M.D.,Ph.D., that id...n,p53, in the pigmentation of skin. Fisher,s stud...r suppressor in other cancers in,the body, p53 als...
Other Medicine Technology:Why Is Polio Spreading in Pakistan? 2Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein 2
Hartman Rongeurs
Echlin Duckbill Bone Rongeurs
Blumenthal Bone Rongeur
Biffer Bone Rongeur
Medicine Products: